Idera Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $7.14
- Today's High:
- $8.67
- Open Price:
- $8.1056
- 52W Low:
- $0.215
- 52W High:
- $9.5209
- Prev. Close:
- $9.2123
- Volume:
- 21875
Company Statistics
- Market Cap.:
- $26.50 million
- Book Value:
- 0.352
- Revenue TTM:
- $49000
- Operating Margin TTM:
- -35422.45%
- Gross Profit TTM:
- $-9247000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -15.19%
- Return on Equity TTM:
- -32.32%
Company Profile
Idera Pharmaceuticals Inc had its IPO on 1996-01-24 under the ticker symbol IDRA.
The company operates in the Healthcare sector and Biotechnology industry. Idera Pharmaceuticals Inc has a staff strength of 13 employees.
Stock update
Shares of Idera Pharmaceuticals Inc opened at $8.11 at the start of the last trading session i.e. 2023-03-24.
The stocks traded within a range of $7.14 - $8.67, and closed at $7.23.
This is a -21.57% slip from the previous day's closing price.
A total volume of 21,875 shares were traded at the close of the day’s session.
In the last one week, shares of Idera Pharmaceuticals Inc have increased by +917.75%.
Idera Pharmaceuticals Inc's Key Ratios
Idera Pharmaceuticals Inc has a market cap of $26.50 million, indicating a price to book ratio of 0.841 and a price to sales ratio of 349.9538.
In the last 12-months Idera Pharmaceuticals Inc’s revenue was $49000 with a gross profit of $-9247000 and an EBITDA of $-17341000. The EBITDA ratio measures Idera Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Idera Pharmaceuticals Inc’s operating margin was -35422.45% while its return on assets stood at -15.19% with a return of equity of -32.32%.
In Q3, Idera Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.
Idera Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.442 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Idera Pharmaceuticals Inc’s profitability.
Idera Pharmaceuticals Inc stock is trading at a EV to sales ratio of 25.277 and a EV to EBITDA ratio of 0.383. Its price to sales ratio in the trailing 12-months stood at 349.9538.
Idera Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $103.68 million
- Total Liabilities
- $19.23 million
- Operating Cash Flow
- $5.48 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Idera Pharmaceuticals Inc ended 2023 with $103.68 million in total assets and $0 in total liabilities. Its intangible assets were valued at $103.68 million while shareholder equity stood at $20.77 million.
Idera Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $19.23 million in other current liabilities, 59000.00 in common stock, $-748045000.00 in retained earnings and $9.93 million in goodwill. Its cash balance stood at $26.80 million and cash and short-term investments were $26.80 million. The company’s total short-term debt was $245,000 while long-term debt stood at $0.
Idera Pharmaceuticals Inc’s total current assets stands at $30.07 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $1.96 million compared to accounts payable of $6.76 million and inventory worth $0.
In 2023, Idera Pharmaceuticals Inc's operating cash flow was $5.48 million while its capital expenditure stood at $0.
Comparatively, Idera Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $7.23
- 52-Week High
- $9.5209
- 52-Week Low
- $0.215
- Analyst Target Price
- $7.8333
Idera Pharmaceuticals Inc stock is currently trading at $7.23 per share. It touched a 52-week high of $9.5209 and a 52-week low of $9.5209. Analysts tracking the stock have a 12-month average target price of $7.8333.
Its 50-day moving average was $0.68 and 200-day moving average was $0.52 The short ratio stood at 3.14 indicating a short percent outstanding of 0%.
Around 2955.9% of the company’s stock are held by insiders while 552.2% are held by institutions.
Frequently Asked Questions About Idera Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.